1. European Medicine Agency.TGN1412: what happened?‐ Suntharalingam & N Panoskaltsishttps://www.ema.europa.eu/en/documents/presentation/tgn1412‐what‐happened‐suntharalingam‐n‐panoskaltsis_en.pdf>
2. The Primary Outcome Fails — What Next?
3. Postmarketing Requirements and Commitments.Downloadable database file. (10/24/2023). 12/1/2023.
4. U.S. Food and Drug Administration Website.Approval package for cetuximab. Accessed March 30 2024.
5. C‐Path Launches Clinical Trial Simulator for Duchenne Muscular Dystrophy Research. Accessed March 29 2024.